Bellevue Life Sciences Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OSR Health, Inc. announced the results of its annual meeting, with stockholders re-electing seven directors and approving key proposals including auditor ratification and an increase in authorized shares.
OSR Health clarifies that Nasdaq's prior communication regarding its Shareholder Loyalty CVR Program was limited to a technical question and not an endorsement.
OSR Health announces Nasdaq communication confirming its Shareholder Loyalty CVR program will not trigger mechanical price adjustments for common stock.
OSR Health, Inc. (formerly OSR Holdings, Inc.) has officially changed its corporate name and revived its Delaware charter, effective June 11, 2026.
OSR Holdings, Inc. has postponed its 2026 Annual Meeting of Stockholders, originally scheduled for June 18, 2026, to allow for further evaluation of matters related to the meeting.
OSR Holdings, Inc. has entered into an Asset Purchase Agreement to acquire the VXM01 intellectual property family from its indirect subsidiary, Vaximm AG, for $30 million.
OSR Holdings, Inc. has filed an independent fairness opinion from Avance Life Sciences AG regarding its $815 million global license agreement for the VXM01 asset with BCM Europe AG.
OSR Holdings, Inc. has entered into a global exclusive license agreement with its largest shareholder, BCM Europe AG, for its VXM01 cancer immunotherapy platform, potentially worth up to $815 million in milestone payments.
OSR Holdings, Inc. has appointed Yeiseok Kim as its new Chief Operating Officer, effective April 16, 2026.
OSR Holdings, Inc. announced a strategic transaction with White Lion Capital, LLC, involving a new convertible note and the retirement of significant warrant overhang.
OSR Holdings, Inc. files an 8-K/A to correct clerical errors in a Global License Agreement for VXM01, clarifying financial terms and parties involved.
OSR Holdings, Inc. has entered a binding term sheet with BCM Europe AG for a global exclusive license of its VXM01 cancer immunotherapy platform, featuring up to $815 million in potential milestone payments.
OSR Holdings inadvertently disclosed preliminary discussions regarding a potential controlling stake in SillaJen and a Pexa-Vec licensing deal for its Vaximm subsidiary.
OSR Holdings, Inc. has officially closed its acquisition of South Korea-based medical device company Woori IO, strengthening its digital health platform.
OSR Holdings' subsidiary Vaximm AG has entered a binding term sheet with BCM Europe AG for a global exclusive license of its VXM01 oral cancer immunotherapy platform, potentially worth up to $845 million.
OSR Holdings' subsidiary Vaximm AG has entered a non-binding term sheet with major shareholder BCM Europe AG for a global license of its VXM01 immunotherapy platform, potentially worth up to $835 million.
OSR Holdings Inc. announced the acquisition of South Korean medical device company Woori IO Co., Ltd. for approximately $10.6 million, aiming to advance non-invasive glucose monitoring technology.
OSRH stockholders approved executive compensation, an equity plan, and a Nasdaq 20% issuance, while electing seven of nine director nominees at their annual meeting.
OSR Holdings, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, facing potential delisting if not resolved by March 4, 2026.
OSR Holdings, Inc. and its CEO face a lawsuit from Chardan Capital Markets, LLC seeking approximately $2.07 million and 34,500 deferred equity shares.
OSR Holdings, Inc. amended its agreements with White Lion Capital, LLC, requiring stockholder approval for certain transactions by September 19, 2025, or facing significant penalties.
OSR Holdings, a healthcare innovation holding company, outlined its hub-and-spoke strategy, recent biotech and medical device acquisitions, and plans for noninvasive glucose monitoring, despite a significant increase in net loss.
OSR Holdings, Inc. announced a non-binding term sheet for its Korean affiliate, OSR Holdings Co., Ltd., to acquire Woori IO Co., Ltd., a developer of noninvasive glucose monitoring technology, aiming to make Woori IO a wholly-owned subsidiary.
OSR Holdings, Inc. announced the immediate resignation of Sang Hyun Kim as an independent director from its Board of Directors, effective June 26, 2025.
8-K: OSR Holdings Secures $1.11 Million in Convertible Note Financing and Amends Equity Line of Credit
OSR Holdings, Inc. has entered into a Note Purchase Agreement for $1.11 million in convertible notes with White Lion Capital, LLC, and amended its Equity Line of Credit (ELOC) agreement to potentially sell up to $78.9 million in common stock.
8-K/A: OSR Holdings Completes Merger with Bellevue Life Sciences Acquisition Corp, Files Amended 8-K
OSR Holdings files an amendment to its previous 8-K report to include audited financial statements, management's discussion and analysis, and unaudited pro forma financial information following its merger with Bellevue Life Sciences Acquisition Corp.
OSR Holdings, Inc. has appointed Dr. Constance Hfer as its new Chief Scientific Officer, effective immediately, to oversee the company's scientific strategy and innovation pipeline.
OSR Holdings enters into a common stock purchase agreement with White Lion GBM Innovation Fund for up to $80 million, providing the company with potential capital for future growth.
OSR Holdings formalizes director and officer protection with new indemnification agreements effective February 14, 2025.
OSR Holdings, formerly Bellevue Life Sciences Acquisition Corp., finalizes its business combination with OSR Holdings Co., Ltd. and will commence trading on the Nasdaq under the ticker symbol OSRH on February 18, 2025.